2nd June 2017, Volume 130 Number 1456

Felix Ram, Elissa McDonald

Due to the recent media coverage1–2 in New Zealand of a Danish retrospective case-control study3 and the risks of out-of-hospital cardiac arrest (OHCA) with the use of non-steroidal anti-inflammatory drugs…

Subscriber content

The full contents of this page is only available to subscribers.

To view this content please login or subscribe

Author Information

Felix SF Ram, Clinical Pharmacologist, College of Health, Massey University, Auckland; Elissa M McDonald, Lecturer, Faculty of Medical and Health Sciences, University of Auckland, Auckland.

Correspondence

Dr Felix SF Ram, Clinical Pharmacologist, College of Health, Massey University, Auckland.

Correspondence Email

fsfram@yahoo.co.uk

Competing Interests

Nil.

References

  1. Nurofen, ibuprofen painkillers linked to cardiac arrest. New Zealand Herald. 2017; 9:05 PM Friday Mar 17. http://www.nzherald.co.nz/lifestyle/news/article.cfm?c_id=6&objectid=11820167 (accessed 4 April 2017). 
  2. OTC labels the key to safe use of NSAID painkillers. Scoop Independent News, New Zealand. 2017; 18 March 2017:9:11pm. http://www.scoop.co.nz/stories/GE1703/S00052/otc-labels-the-key-to-safe-use-of-nsaid-painkillers.htm (accessed 3 April 2017). 
  3. Sondergaard KB, Weeke P, Wissenberg M, et al. Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Eur Heart J Cardiovasc Pharmacother. 2017; 3(2):100–107. 
  4. Medsafe, Ministry of Health, Medicines Data Sheet. Brufen. 2016; 13 May. http://www.medsafe.govt.nz/profs/Datasheet/b/brufenretardtab.pdf (accessed March 28, 2017).
  5. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New Engl J Med. 2005; 352:1092–102. 
  6. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med. 2005; 352:1071–80. 
  7. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 3:332(7553): 1302–8. 
  8. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006 Oct 4; 296(13):1633–44. 
  9. Public Health Advisory—FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). 2005; 4th July. http://www.fda.gov/Drugs/DrugSafety/ucm150314.htm (accessed 3 April, 2017). 
  10. European Medicines Agency. Press release: European Medicines Agency review concludes positive benefit-risk balance for non-selective NSAIDs. 2006; 24th October. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/12/WC500017362.pdf (accessed March 27, 2017). 
  11. European Medicines Agency. Press release: European Medicines Agency concludes action on COX-2 inhibitors. 2005; 27 June. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/01/WC500059088.pdf (accessed March 27, 2017). 

Download

The downloadable PDF version of this article is only available to subscribers.

To view this content please login or subscribe